Why Future of CGT Exists
If you have attended a few cell and gene therapy conferences, you already know how this usually goes.
You walk in with a clear objective. You want to meet the right people, sense where the field is moving, and leave with something that helps you make better decisions. Instead, conversations often turn commercial before they become relevant, and by the end of the day, you have had plenty of interactions but very few that actually move your work forward.
If you are building a therapy, a platform, or a company in this space, that imbalance becomes hard to ignore. You need partners, but you also need time with people who are dealing with the same constraints you are. Regulatory uncertainty, manufacturing bottlenecks, and capital pressure. Those conversations rarely happen when the room is structured around selling rather than sharing.
Future of CGT starts from that point. Not as another event, but as an attempt to change what happens inside the room.
The Content Problem You’ve Probably Sat Through
You have likely seen the same type of presentation more than once.
A CAR-T success story that skips over how long it actually took to get manufacturing under control. A gene therapy case that highlights approval but not the reimbursement negotiations that followed. A panel on “partnering strategies” that concludes, predictably, that strong partnerships are important.
Or the opposite: a deep dive into vector design or assay development that is technically impressive, but leaves half the room wondering how any of it translates into decisions they need to make next quarter.
“People just present whatever they want, which eventually leads to standardized presentations.”
At Future of CGT, we added a filter: does this help someone in the room avoid a mistake, make a decision faster, or rethink something they assumed was fixed?
Instead of “what worked,” you hear about where timelines slipped because manufacturing couldn’t scale. Clinical programs slowed down because assumptions made in preclinical did not hold up. Where a regulatory strategy looked sound on paper but created friction later in development.
“We’d like people to zoom in and share real, specific problems that held them back.”
If you are working in CGT, you know those moments exist. They are just rarely shared in public.
Who This Is Really Built For
This is not about excluding parts of the ecosystem. Service providers, investors, and partners are essential to moving the field forward.
But if you have attended enough conferences, you also know what happens when they dominate the room. The conversation becomes broader, more commercial, and less useful for the people actually developing therapies.
“We do need some breathing room for the people actually developing the therapies.”
If you are building, testing, or scaling something in CGT, that space matters. It allows for more honest conversations and more relevant exchanges. Everyone benefits from that, but only if the balance is right.
About Nick Veringmeier
Nick Veringmeier has spent the past 15 years helping life sciences companies, from early-stage startups to established players, turn strong science into commercial progress.
With a deep interest in science and a hands-on approach, he works with cell and gene therapy teams to sharpen their positioning, improve how they communicate, and build the right partnerships to move programs forward.
As the organizer of Future of CGT, he brings this experience into the room by focusing on real challenges in development, not just the successes.
What You Should Walk Away With
The goal is not to impress you on the day itself. It is to change what happens after. You should leave with people you will actually follow up with. Conversations that continue beyond the event. And a clearer sense of what you need to do next.
I hope people meet others with the same vibe who want to share their knowledge. And, I hope everyone walks away with new connections, follow-up meetings, and action lists.”
In an industry where development timelines stretch over years, I don’t think the difference is one breakthrough, but a series of better decisions made earlier.
Why This Matters Now
We are operating in a very different CGT environment than even a few years ago. Funding is no longer abundant. Investment in the sector has dropped sharply since its 2021 peak, and investors have become far more selective about where they place bets.
At the same time, the underlying challenges have not gone away. Manufacturing remains difficult to scale, especially for autologous therapies. Reimbursement and patient access continue to slow down the transition from clinical success to real-world impact.
Even the narrative around the field has shifted. What used to be framed as rapid growth is now more often described as a reset or recalibration, with more focus on operational discipline and fewer assumptions about easy progress.
You see it in practice. Programs that looked promising struggle to secure follow-on funding. Therapies that reach approval face unexpected barriers to adoption. Entire companies are forced to rethink their strategy, not because the science failed, but because execution proved harder than expected.
“It kind of feels like we’re rooting out the weeds.”
And still, the scientific potential remains strong. The pipeline is large, the demand is real, and long-term growth is expected. That tension is where the field currently sits.
If you are building in this space, you do not need more confirmation that CGT is promising. You need a clearer understanding of where things break, how others are navigating those challenges, and what to do differently next.
That is the context in which the Future of CGT exists.
Not as another conference, but as a room prepared for people who are trying to get therapies across the line, knowing that the hardest part is no longer proving that something can work, but making sure it actually does.